Back to today’s briefing

Story perspectives

EU Approves Vertex's Alyftrek, Transforming Cystic Fibrosis Treatment

7/2/2025

34 6

Summary

Story summary

The European Commission has greenlit Vertex Pharmaceuticals' groundbreaking drug, Alyftrek, for cystic fibrosis patients aged six and older with certain genetic mutations. This innovative once-daily treatment boosts CFTR protein function, significantly improving lung health. With prior approvals in the EU, US, and UK, Alyftrek is set to transform the lives of thousands battling cystic fibrosis across Europe.

1 of 1

Story summary

The European Commission has greenlit Vertex Pharmaceuticals' groundbreaking drug, Alyftrek, for cystic fibrosis patients aged six and older with certain genetic mutations. This innovative once-daily treatment boosts CFTR protein function, significantly improving lung health. With prior approvals in the EU, US, and UK, Alyftrek is set to transform the lives of thousands battling cystic fibrosis across Europe.